1,721,104 research outputs found
CLINICAL MANIFESTATIONS RELATED WITH ANTICARDIOLIPIN ANTIBODIES IN SYSTEMIC LUPUS-ERYTHEMATOSUS - PRELIMINARY-RESULTS OF A PROSPECTIVE-STUDY
No full textPREVALENCE AND CLINICAL ASSOCIATIONS OF ANTICARDIOLIPIN ANTIBODIES IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE-STUDY
No full textGenetics of antiendothelial cell antibodies in systemic lupus erythematosus: the role of HLA-DP alleles
No full textHLA-DR association in rheumatoid arthritis patients and the shared susceptibility epitope hypothesis
No full textIMMUNOSUPPRESSIVE THERAPY IN LUPUS NEPHRITIS: A RANDOMISED TRIAL OF LOW DOSE VERSUS HIGH DOSE INTRAVENOUS CYCLOPHOSPHAMIDE. THE EUROLUPUS NEPHRITIS TRIAL.
No full textOBJECTIVE:
Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that is usually treated with an extended course of intravenous (IV) cyclophosphamide (CYC). Given the side effects of this regimen, we evaluated the efficacy and the toxicity of a course of low-dose IV CYC prescribed as a remission-inducing treatment, followed by azathioprine (AZA) as a remission-maintaining treatment.
METHODS:
In this multicenter, prospective clinical trial (the Euro-Lupus Nephritis Trial [ELNT]), we randomly assigned 90 SLE patients with proliferative glomerulonephritis to a high-dose IV CYC regimen (6 monthly pulses and 2 quarterly pulses; doses increased according to the white blood cell count nadir) or a low-dose IV CYC regimen (6 fortnightly pulses at a fixed dose of 500 mg), each of which was followed by AZA. Intent-to-treat analyses were performed.
RESULTS:
Followup continued for a median of 41.3 months in the low-dose group and 41 months in the high-dose group. Sixteen percent of those in the low-dose group and 20% of those in the high-dose group experienced treatment failure (not statistically significant by Kaplan-Meier analysis). Levels of serum creatinine, albumin, C3, 24-hour urinary protein, and the disease activity scores significantly improved in both groups during the first year of followup. Renal remission was achieved in 71% of the low-dose group and 54% of the high-dose group (not statistically significant). Renal flares were noted in 27% of the low-dose group and 29% of the high-dose group. Although episodes of severe infection were more than twice as frequent in the high-dose group, the difference was not statistically significant.
CONCLUSION:
The data from the ELNT indicate that in European SLE patients with proliferative lupus nephritis, a remission-inducing regimen of low-dose IV CYC (cumulative dose 3 gm) followed by AZA achieves clinical results comparable to those obtained with a high-dose regimen
Coexpression of CD69 and HLADR activation markers on synovial fluid T lymphocytes of patients affected by rheumatoid arthritis: a three-colour cytometric analysis
No full textHLA-DP GENOTYPING IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS - CORRELATIONS WITH AUTOANTIBODY SUBSETS
No full textPROGNOSTIC FACTORS IN RAYNAUDS-PHENOMENON - ANTINUCLEAR ANTIBODIES AND NAILFOLD CAPILLARY MICROSCOPY
No full textANTICARDIOLIPIN ANTIBODIES - THEIR RELATIONSHIP WITH HLA-DR ANTIGENS IN SYSTEMIC LUPUS-ERYTHEMATOSUS
No full textHLA-DP genotyping in patients with systemic lupus erythematosus: correlations with autoantibody subsets
No full textIn order to ascertain whether the HLA-DP locus plays a role in the genetic predisposition for systemic lupus erythematosus (SLE), 42 patients with SLE were typed for 17 different DPBeta haplotypes by locus specific amplification followed by allele specific oligonucleotide hybridization. Sera from the same patients were assayed for the presence of autoantibodies to Sm, RNP, Ro, La and of anticardiolipin antibodies (aCL). DPB1*0301 and DPB1*1401 were increased in patients compared with 107 healthy controls, mainly in those anti-Sm/RNP positive and aCL positive. Remarkably, DPB1*1401 and DPB1*0301 have a nearly identical nucleotide sequence, suggesting that an epitope shared by their membrane products is of major importance for the DP related susceptibility to SLE
- …
